ArticleJournal of traditional Chinese medicine = Chung i tsa chih ying wen pan2026
Berberine alleviates alcoholic liver diseaseactivating intestinal nuclear receptor subfamily 1 group D member 1.
Article in Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
objectivesTo elucidate the hepatoprotective mechanism of berberine (BBR) against alcohol-induced liver injury.
methodsChronic and acute alcohol-induced liver injury models in mice were established to mimic human alcoholic liver disease (ALD). The therapeutic effect of BBR was evaluated in both models. The severity of liver injury, lipid metabolism and circadian clock related factors were assessed using histopathology, biochemical assays, and Western blotting. Intestinal-specific nuclear receptor subfamily 1 group D member 1 (
resultsBBR alleviated hepatic steatosis and inflammation in both chronic and acute ALD models. Mechanistically, BBR activated intestinal REV-ERBα, upregulating intestinal fatty acid desaturase 2 (FADS2) expression, suppressing hepatic sterol regulatory element binding protein-1 (SREBP-1c) and its downstream lipogenic genes. These effects were abolished in intestinal specific Rev-erba knockout mice. BBR was most effective against ALD when administered during the peak expression phase of REV-ERBα (Zeitgeber Time 6).
conclusionsIntestinal REV-ERBα represents a promising therapeutic target for ALD, and chrono-modulated BBR administration may enhance treatment efficacy. This study underscores the role of gut-liver axis in ALD pathogenesis and provides a rationale for developing time-tailored therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.